Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

AIDS

Volumn 16, Issue 16, 2002, Pages 2165-2173

  Walker, Ulrich A ^a   Setzer, Bernhard ^a   Venhoff, Nils ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cytochrome c oxidase; Drug synergism; HIV infection; Lactate; Liver steatosis; Mitochondria; Mitochondrial DNA; Polymerase gamma; Respiratory chain; Reverse transcriptase inhibitors; Treatment

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LIPID; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HEPATITIS; HUMAN; HUMAN CELL; LACTIC ACIDOSIS; LIVER DISEASE; MITOCHONDRION; PRIORITY JOURNAL; SOUTHERN BLOTTING;

ACIDOSIS, LACTIC; CELL LINE; CYCLOOXYGENASE 2; DNA, MITOCHONDRIAL; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; ISOENZYMES; LACTIC ACID; LIPIDS; LIVER DISEASES; MEMBRANE PROTEINS; MITOCHONDRIAL DISEASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 0037045058     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211080-00009     Document Type: Article

References (32)

1. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
2. Brivet FG, Nion I, Megarbane B, Slama A, Brivet M, Rustin P et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: A respiratory chain dysfunction? J Hepatol 2000, 32:364-365.
3. Morris AA, Taanman JW, Blake J, Cooper JM, Lake BD, Malone M, et at. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998, 28:556-563.
4. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999, 30:156-160.
5. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
6. Gerard Y, Maulin L, Yazdanpanah Y, Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: An emerging complication of antiretroviral therapy. AIDS 2000, 14:2723-2730.
7. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley-Usmar VM. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000, 44:496-503.
8. Youssef JA, Badr MZ. Disruption of mitochondrial energetics and DNA synthesis by the anti- AIDS drug dideoxyinosine. Toxicol Lett 1992, 60:197-202.
9. Chariot P, Bonne G, Authier FJ, Marsac C, Gherardi R. Expression of cytochrome c oxidase subunits encoded by mitochondrial or nuclear DNA in the muscle of patients with zidovudine myopathy. J Neurol Sci 1994, 125:190-193.
10. Walker UA, Bickel M, Lütke Volksbeck SI, Ketersen UP, Schofer H, Setzer B et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002, 29:117-121.
11. Lucas GN, Amarasingha A. Sinus histiocytosis with massive lymphadenopathy [letter]. Ceylon Med J 1997, 42:149.
12. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989, 264:11934-11937.
13. Broder S. Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus. Am J Med 1990, 88:2S-7S.
14. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000, 22:685-708.
15. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001, 98:2284-2288.
16. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994, 38:1824-1828.
17. Schultz RA, Swoap SJ, McDaniel LD, Zhang B, Koon EC, Garry DJ, et al. Differential expression of mitochondrial DNA replication factors in mammalian tissues. J Biol Chem 1998, 273:3447-3451.
18. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994, 38:2743-2749.
19. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39:625-628.
20. Huizing M, Ruitenbeek W, Van den Heuvel LP, Dolce V, lacobazzi V, Smeitink JA, et al. Human mitochondrial transmembrane metabolite carriers: Tissue distribution and its implication for mitochondrial disorders. J Bioenerg Biomembr 1998, 30:277-284.
21. Gilkerson RW, Margineantu DH, Capaldi RA, Selker JM. Mitochondrial DNA depletion causes morphological changes in the mitochondrial reticulum of cultured human cells. FEBS Lett 2000, 474:1-4.
22. Paran N, Geiger B, Shaul Y. HBV infection of cell culture: Evidence for multivalent and cooperative attachment. EMBO J 2001, 20:4443-4453.
23. Hobbs GA, Keilbaugh SA, Rief PM, Simpson MV. Cellular targets of 3′-azido-3′-deoxythymidine: An early (non-delayed) effect on oxidative phosphorylation. Biochem Pharmacol 1995, 50:381-390.
24. Barile M, Valenti D, Hobbs GA, Abruzzese MF, Keilbaugh SA, Passarella S, et al. Mechanisms of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase. Biochem Pharmacol 1994, 48:1405-1412.
25. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med 2000, 6:93-96.
26. Barile M, Valenti D, Passarella S, Quagliariello E. 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol 1997, 53:913-920.
27. Weidner DA, Sommadossi JP. 3′-Azido-3′-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells. Mol Pharmacol 1990, 38:797-804.
28. Valenti D, Barile M, Quagliariello E, Passarella S. Inhibition of nucleoside diphosphate kinase in rat liver mitochondria by added 3′-azido-3′-deoxythymidine. FEBS Letters 1999, 444:291-295.
29. de la Asuncion JG, del Olmo ML, Sastre J, Pallardo FV, Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999, 29:985-987.
30. Hayakawa M, Ogawa T, Sugiyama S, Tanaka M, Ozawa T. Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem Biophys Res Commun 1991, 176:87-93.
31. Maga G, Hubscher U, Pregnolato M, Ubiali D, Gosselin G, Spadari S. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs. Antimicrob Agents Chemother 2001, 45:1192-1200.
32. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med 1999, 5:1048-1051.